SETDB1 binding to SMAD3 methylates and suppresses T cell receptor-induced IL-2 transcription, presenting an additional mechanism of SETDB1 involvement in ovarian cancer tumorigenesis [75,106]. Here, SETDB1 is linked to ovarian cancer.